Clovis Oncology Receives Consensus Recommendation of “Buy” from Analysts (NASDAQ:CLVS)
Shares of Clovis Oncology (NASDAQ:CLVS) have received a consensus rating of “Buy” from the ten brokerages that are covering the company, Analyst Ratings.Net reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $74.00.
A number of research firms have recently commented on CLVS. Analysts at Stifel Nicolaus upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, June 5th. They now have a $50.00 price target on the stock. Separately, analysts at Stifel upgraded shares of Clovis Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, June 5th. They now have a $50.00 price target on the stock. Finally, analysts at Goldman Sachs cut their price target on shares of Clovis Oncology from $85.00 to $50.00 in a research note on Wednesday, June 4th. They now have a “neutral” rating on the stock.
Clovis Oncology (NASDAQ:CLVS) traded down 1.54% during mid-day trading on Wednesday, hitting $44.05. The stock had a trading volume of 133,512 shares. Clovis Oncology has a one year low of $36.11 and a one year high of $93.33. The stock has a 50-day moving average of $50. and a 200-day moving average of $63.28. The company’s market cap is $1.494 billion.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.06. The company had revenue of $13.60 million for the quarter. Analysts expect that Clovis Oncology will post $-3.89 EPS for the current fiscal year.
Clovis Oncology, Inc is a United States-based biopharmaceutical company. The Company develops anti-cancer agents.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.